Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific

By LabMedica International staff writers
Posted on 25 Sep 2026

Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics and precision medicine across Southeast Asia, Australia, and New Zealand. More...

The initiative builds on a long-term relationship that combines global clinical and diagnostic expertise with a broad regional laboratory network and local market knowledge. In certain markets, LifeStrands will operate as “LifeStrands in collaboration with Mayo Clinic Laboratories” to reflect the joint offering.

The collaboration centers on genomics delivered through LifeStrands Genomics. The parties plan to broaden access to advanced molecular and genomic testing with applications spanning identification of genetic conditions, risk assessment, diagnosis, and treatment planning. The goal is to enable healthcare providers to incorporate clinically relevant genomic findings into more personalized patient care across the region.

In support of clinical adoption, the organizations will pursue joint scientific initiatives, education, and thought leadership to help integrate genomics into care pathways. Pathology Asia provides pathology, molecular, and genomic testing through a network of internationally accredited laboratories operating across Singapore, Malaysia, Indonesia, Thailand, Vietnam, the Philippines, and Australia. LifeStrands Genomics comprises specialist laboratories in Singapore and Australia, along with DNA Laboratories, providing testing across oncology, reproductive health, inherited disorders, and wellness.

“Healthcare providers across Southeast Asia, Australia and New Zealand are increasingly seeking advanced diagnostic solutions to guide patient care. Our collaboration with PAH and LifeStrands Genomics reflects our commitment to a long-term strategic relationship that unites complementary strengths in laboratory diagnostics and genomics. Through this collaboration, we are bringing advanced diagnostic capabilities closer to patients and equipping healthcare providers with the insights needed to deliver personalised care,” said William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories.

“Mayo Clinic Laboratories' investment marks an important milestone in our relationship and a strong foundation for the next phase of diagnostic innovation across the region," said Christopher Ting, M.D., founder and CEO of Pathology Asia Holdings. "Combining Mayo Clinic Laboratories' global clinical and scientific expertise with PAH's regional diagnostic capabilities and network will enable us to broaden access to advanced testing and increase access to genomics and precision medicine capabilities across Southeast Asia, Australia and New Zealand.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.